Konjac glucomannan was 1st used and studied by the Chinese, and its medicative properties were 1st represented within the ShenNong pharmacology throughout the Western Han dynasty (ca 206 before Christ to 08 AD). Konjac flour has been historically created through process corms, the underground storage organs. when boiling with plant ash, the flour is consumed as cake or gel. Its therapeutic effects are believed to result to serotonin. Chinese have used konjac glucomannan for over a pair of thousand years to treat conditions like respiratory disorder, hernia cough, breast pain, burns, and diseases of the skin. The leaves have jointly been used as an insect repellant. within the sixth century AD, konjac glucomannan was introduced to Japan as a medicative product.
Glucomannan is usually utilized in foods, drinks, and cosmetics for its gelling properties. It’s been approved by the Food and Drug Administration (FDA) since 1994 as an additive and since 1996 as a binder in meat merchandise. China is now the largest producer of konjac, and Japan is the second largest. In China, close to four hundred factories manufacture konjac flour.
Effects on lung cancer
Clinical result in animals
A study from China has investigated the flexibility of konjac powder to inhibit lung or respiratory organ cancers in mice. Mice ate a diet of eight percent konjaku powder, mixed in with a typical diet, showed a discount in cancer rate from 70.87% within the positive management set to nineteen.38% within the set fed with konjac powder. Lung tumors or cancers were lured with N -methyl- N ′-nitro- N -nitrosoguanidine (MNNG), the study reported no adverse reactions to the konjaku powder.
Clinical result in man
Research reveals no clinical knowledge concerning the employment or usage of glucomannan for lung cancer.
Glucomannan given to rats at dosages of five hundred mg/kg/day for eighteen months noticed no toxicity. Data proposes minor GI effects (eg, diarrhea, abdominal pain, flatulence) occur with dosages more thanfive g daily.
Given the fact of reducing blood sugar levels, caution ought to be utilized in patients receiving oral hypoglycaemicagents, insulin, or various medicines that lower aldohexose levels. Plus, glucomannan could cut back the bioavailability of alternative oral medications. Thus, it’s counseled to require alternative medications one hour before or four hours before glucomannan administration.